Evidence map›Paper›PMID 37928843›Full record

ArticleRSC advances2023

Design, synthesis, and biological evaluation of new pyrimidine-5-carbonitrile derivatives as novel anti-cancer, dual EGFR

Nada Reda, Ahmed Elshewy, Hesham I El-Askary, Khaled O Mohamed, Amira A Helwa

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Nada RedaPharmaceutical Organic Chemistry Department, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology (MUST) 6th of October City Egypt amira.helwa@must.edu.eg Nada.reda@must.edu.eg.ORCID https://orcid.org/0000-0002-7781-4489
Ahmed ElshewyPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University Kasr El-Aini Street Cairo 11562 Egypt khaled.mohamed@pharma.cu.edu.eg ahmed.elshewy@pharma.cu.edu.eg.ORCID https://orcid.org/0000-0002-4493-3158
Hesham I El-AskaryDepartment of Pharmacognosy, Faculty of Pharmacy, Cairo University Kasr El-Aini Street Cairo 11562 Egypt hesham.elaskary@pharma.edu.eg.ORCID https://orcid.org/0000-0001-7764-6588
Khaled O MohamedPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University Kasr El-Aini Street Cairo 11562 Egypt khaled.mohamed@pharma.cu.edu.eg ahmed.elshewy@pharma.cu.edu.eg.ORCID https://orcid.org/0000-0002-2293-5363
Amira A HelwaPharmaceutical Organic Chemistry Department, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology (MUST) 6th of October City Egypt amira.helwa@must.edu.eg Nada.reda@must.edu.eg.ORCID https://orcid.org/0000-0002-3330-476X
Cairo University · EGMisr University for Science and Technology · EGSinai University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A novel series of pyrimidine-5-carbonitrile derivatives was designed, synthesized, then evaluated for their cytotoxic activity as novel anti-cancer with dual EGFR

Identifiers

PMID37928843
PMCPMC10620772
OpenAlexW4388224522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.